STING1 and neoplasm: Because IMSA172 is in principle suitable for conjugation with a variety of antibodies and other tumor-targeting agents, future research with different ADCs containing the IMSA172 payload should reveal the safety and efficacy of activating STING in different types of tumors through systemic delivery of STING ADCs.